This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C13 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the cancer registration date) |
| B. Synonyms | Hypopharyngeal cancer, laryngopharyngeal cancer, hypopharyngeal squamous cell carcinoma, Hypopharyngeal cancer, Laryngopharyngeal carcinoma |
| C. Adult onset | Very high — mainly men in their 50s–70s; includes the hypopharynx other than the pyriform sinus (C12): postcricoid region, posterior pharyngeal wall |
| 1. History | History of hypopharyngeal cancer classification, discovery of the Plummer-Vinson association with postcricoid cancer, changes in the treatment paradigm |
| 2. Causes | Smoking, alcohol, combined exposure (highest risk), Plummer-Vinson syndrome, occupational carcinogens |
| 3. Genetics | TP53 and CDKN2A variants, EGFR overexpression, PIK3CA and NOTCH1 variants, field cancerization genes |
| 4. General epidemiology | 3–5% of all head and neck cancers; hypopharynx excluding the pyriform sinus (C13) about 100–200 cases per year (Korea) |
| 5. Pathophysiology | Field cancerization, multistep mucosal carcinogenesis, repeated chemical irritation from swallowing, involvement of chronic reflux |
| 6. Symptoms | Dysphagia, sore throat, otalgia, neck mass, hoarseness, dyspnea, weight loss |
| 7. Signs | Cervical lymphadenopathy, laryngoscopic findings, vocal cord paralysis, pooling of saliva, stridor |
| 8. Screening | No national screening; early endoscopic evaluation when warning signs are present, with concurrent upper gastrointestinal endoscopy |
| 9. Diagnosis | Laryngoscopy + biopsy, CT/MRI, PET-CT, panendoscopy, TNM staging (AJCC 8th edition) |
| 10. Treatment | Laryngopharyngectomy, larynx preservation with CCRT, TPF induction chemotherapy, pembrolizumab/nivolumab immunotherapy |
| 11. Prognosis | Overall 5-year survival 30–35%; by stage, stage I 100%, stage IV 20–30%; the poorest-prognosis head and neck cancer |
| 12. Prevention | Smoking cessation, moderation of alcohol intake, correction of iron deficiency, regular endoscopy, early referral for otalgia/odynophagia |
| 13. References | Forastiere AA et al. N Engl J Med 2003 and 9 other papers |
The hypopharynx is the lower region of the pharynx extending from behind the larynx to the esophageal inlet, and in the ICD-10 classification it is subdivided into C12 (pyriform sinus) and C13 (other hypopharynx: postcricoid region, posterior pharyngeal wall, vallecula, etc.). C13 collectively refers to malignant neoplasms of the rest of the hypopharynx excluding the pyriform sinus (C12). Historical descriptions of hypopharyngeal cancer began in the late 19th century, and an important milestone was Turner's 1901 report linking postcricoid carcinoma with Plummer-Vinson syndrome (iron deficiency anemia + dysphagia). Postcricoid carcinoma is strongly associated with Plummer-Vinson syndrome, especially in Northern European women, and in this respect it is epidemiologically distinct from carcinoma originating in the pyriform sinus.
As surgical techniques advanced in the early 20th century, pharyngectomy began to be performed for carcinoma of the hypopharyngeal posterior pharyngeal wall, and with advances in radiotherapy the possibility of nonsurgical treatment was explored in the 1950s–70s. From the 1980s, the combined effect of radiotherapy and chemotherapy began to be systematically tested in head and neck cancer; in particular, the 1991 VA Laryngeal Cancer Study Group study and the 1996 EORTC/GETTEC study showed the possibility of larynx preservation in head and neck cancers including hypopharyngeal cancer. After the introduction of IMRT, radiotherapy outcomes and functional preservation in hypopharyngeal cancer improved from the 2000s. Recently, new treatment concepts such as transoral robotic surgery (TORS), immune checkpoint inhibitors, and neoadjuvant immunochemotherapy combinations are under clinical investigation.
In Korea, hypopharyngeal cancer data have accumulated along with the systematic development of head and neck oncology, and multicenter studies have been conducted, centered on the Korean Society for Head and Neck Cancer Research. Carcinomas originating in the postcricoid region and posterior pharyngeal wall, classified under ICD-10 code C13, differ in part from those originating in the pyriform sinus (C12) in clinical characteristics and prognosis, so recognizing them separately is clinically important.
The main causes of hypopharyngeal cancer (C13) are smoking and alcohol, and it shares the same risk factor structure as pyriform sinus cancer (C12). Smoking causes DNA damage and cellular mutations through direct exposure of the hypopharyngeal mucosa to carcinogens in tobacco smoke. The risk of hypopharyngeal cancer increases linearly with the amount smoked, and smokers of 30 pack-years or more have a risk more than 10 times that of nonsmokers. Alcohol acts through the mucosal toxicity of alcohol itself and the carcinogenicity of its metabolite acetaldehyde. Combined exposure to smoking and alcohol increases the risk exponentially compared with either exposure alone.
In postcricoid carcinoma, Plummer-Vinson (Patterson-Kelly) syndrome is a specific risk factor. Mucosal atrophy and fragility due to chronic iron deficiency anemia promote carcinogenesis of the postcricoid mucosa, and a strong association with postcricoid carcinoma has been reported in Scandinavian women. In this case, the risk decreases when the mucosa normalizes with iron supplementation. Gastroesophageal reflux has also been proposed as a factor causing chronic irritation of the hypopharyngeal mucosa, but the strength of evidence is lower than for smoking and alcohol. Exposure to occupational carcinogens (asbestos, sulfuric acid vapor, formaldehyde) is also an ancillary risk factor.
HPV (human papillomavirus) is established as a major cause of carcinoma of the tonsil and base of tongue in the oropharynx (C10), but its role in hypopharyngeal cancer (C12, C13) is markedly smaller than in the oropharynx. Some studies report an HPV positivity rate of 5–15% in hypopharyngeal cancer, but its clinical significance is limited. Thus, in hypopharyngeal cancer the smoking- and alcohol-related carcinogenic pathway is overwhelmingly predominant, with pathophysiology and prognostic characteristics distinct from HPV-related head and neck cancer.
The molecular genetic characteristics of hypopharyngeal cancer follow the typical pattern of smoking-associated head and neck squamous cell carcinoma (HNSCC). TP53 is the most frequently somatically mutated gene, with deletions or loss-of-function variants observed in 40–60% of hypopharyngeal cancers. TP53 variants are associated with the characteristic smoking-induced mutational signature (mutational signature SBS4). CDKN2A (p16) promoter methylation or deletion causes escape from cell-cycle control and is found in 60–80% of hypopharyngeal cancers. This is the opposite of the p16 overexpression (caused by E7) in HPV-positive oropharyngeal cancer.
EGFR protein overexpression is found in the majority (70–90%) of hypopharyngeal squamous cell carcinomas, and gene amplification is observed in about 10–15%. EGFR overexpression is associated with a poor prognosis and provides the rationale for cetuximab targeted therapy. PIK3CA variants are reported in about 10–15% and NOTCH1 variants in about 10–20%, and they are being explored as new therapeutic targets. PTEN loss further activates the PIK3CA/AKT pathway.
On whole-genome analysis, hypopharyngeal cancer is characterized by high somatic copy number alterations (SCNA) and complex chromosomal rearrangements, reflecting high genomic instability. Tumor mutational burden (TMB) is on average high in smoking-related HNSCC, providing a biological basis for response to immune checkpoint inhibitors. PD-L1 expression is positive in about 40–70% of hypopharyngeal HNSCC, and the CPS score is used to predict treatment response. The alcohol metabolism-related ALDH2 variant (rs671) is common in East Asians and is associated with an increased risk of hypopharyngeal carcinogenesis due to acetaldehyde accumulation.
Hypopharyngeal cancers other than the pyriform sinus classified under C13 (postcricoid region, posterior pharyngeal wall, overlapping or unspecified hypopharyngeal sites) account for about 15–35% of all hypopharyngeal cancers. The overall incidence of hypopharyngeal cancer is relatively rare, at about 0.5–1% of all cancers. In Korea, about 400–600 cases of hypopharyngeal cancer (C12 and C13 combined) occur per year, of which those originating in the postcricoid region and posterior pharyngeal wall (C13) are estimated at about 20–30%. That is, C13 alone accounts for about 100–200 cases per year.
Postcricoid carcinoma is unusually more common in women (the Plummer-Vinson-associated subtype); its incidence was formerly high in Northern European women but has declined greatly with prevention of iron deficiency and improved nutrition. In Korea and East Asia, carcinoma originating in the pyriform sinus far outnumbers postcricoid carcinoma, and men account for more than 90%. Posterior pharyngeal wall carcinoma is rare, at about 5–15% of all hypopharyngeal cancers. The stage distribution at diagnosis is poor, similar to C12, with about 60–70% found at stage III–IV. Distant metastasis is present at diagnosis in about 10–20%.
In Western countries, incidence has been gradually declining along with falling smoking rates, but in aging societies a sharp decrease in the absolute number of cases is limited. In East Asia, given drinking culture and smoking rates, incidence is expected to persist for a considerable period. Second primary cancers such as esophageal cancer (sharing smoking and alcohol as risk factors), lung cancer, and oral cancer occur synchronously or metachronously at a high rate, so they must always be kept in mind during follow-up examinations.
The pathogenesis of hypopharyngeal cancer is explained by the concepts of field cancerization and multistep carcinogenesis. Carcinogens from smoking and alcohol chronically expose the entire mucosa of the upper aerodigestive tract, so that independent genetic alterations accumulate over a wide mucosal area including the hypopharynx. This is called a 'mucosal field defect,' and it underlies the synchronous or metachronous multiple cancers arising at several sites, including the pyriform sinus, postcricoid region, posterior pharyngeal wall, oropharynx, esophagus, and lung. In particular, because the hypopharynx and esophagus are anatomically continuous, synchronous hypopharyngeal and esophageal cancers are clinically common.
At the molecular level, early damage to tumor suppressor genes such as TP53 and CDKN2A is followed by activation of the EGFR signaling pathway (RAS-MAPK, PI3K-AKT), angiogenesis (VEGF overexpression), epithelial-mesenchymal transition (EMT), destruction of the basement membrane and local invasion through activation of MMPs (matrix metalloproteinases), and finally acquisition of distant metastatic capacity. The hypopharyngeal mucosa receives repeated mechanical and chemical irritation during swallowing, and contact with gastric acid and bile during gastroesophageal reflux can cause additional injury.
In postcricoid carcinoma, mucosal atrophy and epithelial fragility due to iron deficiency are added as important mechanistic factors. When normal mucosal defenses are impaired, exposure to carcinogens causes DNA damage more efficiently. In terms of lymphatic spread, the hypopharynx has a rich submucosal lymphatic network, so metastasis to the cervical lymph nodes (level II–IV, retropharyngeal node) occurs early. For this reason, cervical metastasis has often already occurred even when the primary tumor is small, so most cases are at an advanced stage at diagnosis.
The symptoms of hypopharyngeal cancer (C13) overlap considerably with those of C12 (pyriform sinus cancer), but the emphasis differs by anatomic site. Dysphagia is the most common major symptom; it begins with discomfort or a sensation of obstruction when swallowing solid food and, as it progresses, soft and liquid diets also become difficult to swallow. Odynophagia is related to ulceration or infection of the tumor surface. In posterior pharyngeal wall carcinoma, dysphagia is particularly prominent from an early stage. In postcricoid carcinoma, in the context of Plummer-Vinson syndrome, it may present as worsening symptoms in a patient who already had dysphagia.
Otalgia is referred pain via the vagus or glossopharyngeal nerve, occurring in the ear on the same side as the lesion. Unilateral otalgia without an otologic cause is an indication for immediate pharyngeal and laryngeal evaluation. A neck mass is present at the first visit in about 40–60%, with a painless, firm cervical lymph node palpable. Hoarseness suggests direct laryngeal invasion or recurrent laryngeal nerve palsy. In advanced cases, dyspnea, aspiration cough, voice change, and persistent cough appear. Aspiration pneumonia occurs as a complication of swallowing impairment. Systemic symptoms such as weight loss and general weakness result from the combination of malnutrition and the metabolic effects of cancer.
The mean symptom duration before diagnosis is about 3–9 months, because the symptoms are nonspecific, so patients delay seeking medical consultation or mistake them for gastroesophageal reflux or pharyngitis. A smoker or drinker with any of otalgia, dysphagia, or a neck mass persisting for 3 weeks or more should be evaluated immediately by a head and neck specialist.
The most important physical finding is cervical lymphadenopathy. Firm, nontender lymph nodes are palpated around the jugular vein (level II–IV) or in the retropharyngeal space. A neck that feels hard or nodes fixed to the internal jugular vein or carotid artery suggest a locally advanced lesion corresponding to T4b. Flexible or rigid laryngoscopy reveals raised, ulcerative, or irregular mucosal lesions in the posterior pharyngeal wall or postcricoid region. Posterior pharyngeal wall lesions are relatively well seen on endoscopy, but postcricoid lesions lie behind the esophageal inlet and are difficult to observe without direct laryngoscopy.
Vocal cord paralysis is a sign of recurrent laryngeal nerve invasion. Unilateral vocal cord fixation in hypopharyngeal cancer means T3 or higher (fixed vocal cord) or laryngeal invasion. Salivary pooling is the finding of saliva pooled in the pyriform sinus or posterior pharyngeal wall, suggesting swallowing dysfunction and anatomic abnormality caused by the tumor. In advanced cases, inspiratory stridor is observed, which indicates an emergency due to airway compression. Invasion of the neck skin or cutaneous metastasis of the tumor is very rare. Blood tests may show hypoalbuminemia due to malnutrition, iron deficiency anemia, and abnormal liver function.
Assessment of general condition (ECOG score), nutritional status (albumin, BMI, rate of weight loss), and airway status before diagnosis is important for treatment planning. With severe malnutrition, nutritional supplementation via a nasogastric tube or percutaneous endoscopic gastrostomy (PEG) is needed before treatment.
No national cancer screening program for hypopharyngeal cancer (C13) is operated in Korea, because incidence is low and the cost-effectiveness of large-scale population screening has not been demonstrated. In practice, early recognition of warning symptoms and prompt specialist referral is the most effective early detection strategy. Guidelines that standardize specialist referral within 2 weeks when warning signs (otalgia, dysphagia, or a neck mass persisting for 3 weeks or more) are identified, such as the UK 'Two-Week Wait' policy, contribute to early detection.
For high-risk groups (smokers, drinkers, men aged 50 or older, women with Plummer-Vinson syndrome), periodic pharyngeal and laryngeal evaluation using flexible laryngoscopy is clinically meaningful. This test can be performed in the outpatient clinic without anesthesia in under 5 minutes and allows direct identification of abnormalities of the hypopharyngeal mucosa. Especially in patients with a neck mass, immediate laryngoscopy and biopsy are essential.
Because synchronous hypopharyngeal and esophageal cancers are common, patients suspected of or diagnosed with hypopharyngeal cancer must have the entire esophagus evaluated at the same time by esophagogastroduodenoscopy. Narrow-band imaging (NBI) or Lugol's iodine staining allows more sensitive detection of esophageal dysplasia and early esophageal cancer. Chest CT to rule out lung metastasis is also included in the diagnostic workup.
Hypopharyngeal cancer (C13) is confirmed by direct laryngoscopy with biopsy. Because postcricoid and posterior pharyngeal wall lesions can be difficult to see with flexible endoscopy, direct laryngoscopy under general anesthesia is essential. At the same time, panendoscopy, which includes esophagoscopy and bronchoscopy, is performed to check for synchronous multiple primary cancers.
Among imaging studies, contrast-enhanced CT (neck, chest, abdomen) is central for evaluating tumor extent, cervical lymph node metastasis, and distant metastasis. MRI has high soft-tissue resolution and evaluates important anatomic relationships, such as retropharyngeal space invasion, proximity to the carotid artery, and prevertebral fascia invasion, more accurately than CT. PET-CT is used for evaluating systemic distant metastasis and assessing treatment response. Endoscopic ultrasound (EUS) can be used as an adjunct for evaluating cervical lymph nodes and the hypopharyngeal–esophageal junction.
In AJCC 8th edition TNM staging, C13 (hypopharynx other than the pyriform sinus) applies the same T-stage criteria as the pyriform sinus (C12). T1 is confined to one subsite; T2 involves more than one subsite or the larynx; T3 is vocal cord fixation; T4a is invasion of adjacent organs (thyroid cartilage, cricoid cartilage, thyroid gland, hyoid bone, neck soft tissue); and T4b is invasion of the prevertebral fascia, carotid artery, or mediastinum. When squamous cell carcinoma is confirmed on biopsy, PD-L1 CPS score, TMB, and EGFR expression testing are additionally performed and reflected in the treatment plan.
Treatment of hypopharyngeal cancer (C13) is determined by stage and patient condition. In early lesions (T1N0–T2N0), surgery or radiotherapy alone is possible, but postcricoid and posterior pharyngeal wall carcinomas are rarely detected early. For posterior pharyngeal wall carcinoma, the proportion that can be curatively treated with radiotherapy alone is relatively higher than for the pyriform sinus. The standard treatment for locally advanced lesions (T3–T4a, N+) is CCRT (concurrent chemoradiotherapy). Radiation of 66–70 Gy is delivered by IMRT to the hypopharyngeal primary site and cervical lymph nodes, with cisplatin 100 mg/m² given every 3 weeks as the concurrent chemotherapy.
Induction chemotherapy (induction CTx) followed by CCRT is used for T4, bulky N stage, or when larynx preservation is the goal. The TPF regimen (docetaxel + cisplatin + 5-FU) is the standard induction regimen, and patients proceed to CCRT when a complete response (CR) or partial response (PR) is achieved. With an insufficient response, treatment is switched to surgery. When surgery is indicated, total laryngopharyngectomy + neck dissection is performed, with reconstruction using a free jejunal flap or free radial forearm flap. Adjuvant CCRT is given after surgery when high-risk pathologic factors (positive margins, extracapsular extension of lymph nodes) are present.
For first-line treatment of recurrent/metastatic hypopharyngeal cancer, based on the KEYNOTE-048 study, pembrolizumab ± chemotherapy (platinum + 5-FU) is the standard of care for CPS≥1. The EXTREME regimen (cetuximab + cisplatin/carboplatin + 5-FU) is an option for patients with low PD-L1 expression. As second-line treatment, nivolumab is approved for platinum-refractory head and neck squamous cell carcinoma. Recently, new combination regimens such as pembrolizumab + lenalidomide are under clinical investigation. In palliative care, a multidisciplinary team approach focused on maintaining quality of life and symptom management (pain, dysphagia, airway securing) is essential.
Hypopharyngeal cancer has the poorest prognosis among head and neck cancers, with an overall 5-year survival rate of about 30–35%. Carcinomas originating in the postcricoid region and posterior pharyngeal wall in the C13 category show a similar or, in some studies, poorer prognosis. By stage, survival is reported as about 100% for stage I, about 60–70% for stage II, about 45–55% for stage III, about 25–35% for stage IVA, and about 10–20% for stage IVB (distant metastasis). The high proportion of stage III–IV at diagnosis lowers overall survival.
Prognostic factors include T stage, N stage, margin status, presence of vocal cord paralysis, ECOG performance score, nutritional status (albumin level), and pretreatment EBV-DNA (of limited significance in hypopharyngeal cancer). There are reports that posterior pharyngeal wall carcinoma has a slightly poorer prognosis than pyriform sinus carcinoma, but data are limited. A complete response to induction chemotherapy is a positive predictor of long-term survival. With PD-L1 CPS≥20, the response rate to pembrolizumab monotherapy is high.
In terms of recurrence patterns, both local recurrence and distant metastasis are common, with metastasis to the lung, liver, bone, and mediastinum being of particular concern. Post-treatment follow-up is performed every 2–3 months for the first 2 years and at 6-month intervals thereafter, including imaging (CT or PET-CT) and laryngoscopy. Upper gastrointestinal endoscopy and chest CT should be included in follow-up to detect metachronous second primary cancers (esophageal cancer, lung cancer) early. In terms of post-treatment quality of life (QoL), swallowing function, voice, and airway status are key elements, and swallowing rehabilitation and voice therapy play important roles.
The most important prevention of hypopharyngeal cancer is smoking cessation and moderation of alcohol intake. Quitting smoking leads over time to recovery of mucosal damage and reduced cancer risk, approaching the level of nonsmokers after 10–15 years. Reducing or stopping alcohol intake lowers the risk of hypopharyngeal cancer independently of smoking. When the two risk factors are combined, the preventive effect is also combined. Industrial hygiene management of exposure to occupational carcinogens (asbestos, sulfuric acid vapor, formaldehyde) is a secondary preventive measure.
In Plummer-Vinson syndrome, early diagnosis and iron supplementation can lower the risk of postcricoid carcinoma. Women with iron deficiency anemia accompanied by dysphagia should undergo endoscopic evaluation immediately. Adequate nutrition (rich in vegetables, fruits, and antioxidants) and weight maintenance also contribute to cancer prevention. In patients with gastroesophageal reflux, reducing exposure of the hypopharyngeal mucosa with proton pump inhibitor therapy may have an indirect preventive effect.
Early recognition of warning signs and prompt referral to a head and neck specialist in primary care is key to improving prognosis through early detection. Education on clinical guidelines is needed so that smokers and drinkers with any of otalgia, dysphagia, a neck mass, or hoarseness persisting for 3 weeks or more are immediately referred to an otolaryngologist or head and neck surgeon. HPV vaccination is effective in preventing oropharyngeal cancer, but evidence for direct prevention of hypopharyngeal cancer is still lacking.